Quick Answer
Connect Biopharma Holdings Ltd reported Operating Income Loss of -$58.07 million for the year ending 2025.
- Connect Biopharma Holdings Ltd showed a decrease of -158.7% in Operating Income Loss from 2024 to 2025.
- This data is from Connect Biopharma Holdings Ltd's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), Connect Biopharma Holdings Ltd's Operating Income Loss has grown by 15.9%.
- Historical annual values: Fiscal year 2025: -$58.07 million | Fiscal year 2024: -$22.45 million | Fiscal year 2023: -$69.06 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: